Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 micrograms ethinyl estradiol and 2.00 mg dienogest on the hemostatic system
Forty healthy female volunteers aged between 19 and 35 years (27.3 +/- 4.1 years) with normal menstrual cycles were included in a double-blind, randomized, placebo-controlled study to investigate the influence on the hemostatic system of an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest, which is a 19-norprogestin without a 17 alpha-ethinyl group. At baseline and during one treatment cycle, 12 hemostatic parameters were measured on cycle days 7, 14, and 21. The hemostatic parameters were categorized as either procoagulatory, anticoagulatory and profibrinolytic, or antifibrinolytic and indicative of fibrin turnover. Differences between placebo and 30 micrograms ethinyl estradiol and 2.00 mg dienogest of plasma levels of hemostatic parameters on cycle days 21 of the precycle and treatment cycle were chosen as target variables. Prothrombin fragment 1 + 2 (F 1 + 2) was chosen as the main target variable. Equivalence of F 1 + 2 between placebo and active treatment was noted. Among the procoagulatory factors, only factor VII activity was found to be increased over placebo in the active treatment group, but decreased in the placebo group. Protein C activity increased during the treatment with 30 micrograms ethinyl estradiol and 2.00 mg dienogest, and was higher than that of the placebo group in which this parameter decreased during the treatment cycle. There was a corresponding increase in fibrinolytic activity being reflected by higher plasminogen levels in the active treatment group in comparison with placebo. An increase was noted for the fibrinolytic parameter D-dimer. Apart from isolated measurements, the parameters remained in their respective normal ranges. The data combine to suggest that 30 micrograms ethinyl estradiol and 2.00 mg dienogest has a balanced effect on the hemostatic system stimulating both procoagulatory and fibrinolytic activity.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1997 |
|---|---|
| Erschienen: |
1997 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Contraception - 56(1997), 2 vom: 22. Aug., Seite 67-75 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Spona, J [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 31.10.1997 Date Revised 26.08.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM092668844 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM092668844 | ||
| 003 | DE-627 | ||
| 005 | 20231222091318.0 | ||
| 007 | tu | ||
| 008 | 231222s1997 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0309.xml |
| 035 | |a (DE-627)NLM092668844 | ||
| 035 | |a (NLM)9315414 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Spona, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 micrograms ethinyl estradiol and 2.00 mg dienogest on the hemostatic system |
| 264 | 1 | |c 1997 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 31.10.1997 | ||
| 500 | |a Date Revised 26.08.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Forty healthy female volunteers aged between 19 and 35 years (27.3 +/- 4.1 years) with normal menstrual cycles were included in a double-blind, randomized, placebo-controlled study to investigate the influence on the hemostatic system of an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest, which is a 19-norprogestin without a 17 alpha-ethinyl group. At baseline and during one treatment cycle, 12 hemostatic parameters were measured on cycle days 7, 14, and 21. The hemostatic parameters were categorized as either procoagulatory, anticoagulatory and profibrinolytic, or antifibrinolytic and indicative of fibrin turnover. Differences between placebo and 30 micrograms ethinyl estradiol and 2.00 mg dienogest of plasma levels of hemostatic parameters on cycle days 21 of the precycle and treatment cycle were chosen as target variables. Prothrombin fragment 1 + 2 (F 1 + 2) was chosen as the main target variable. Equivalence of F 1 + 2 between placebo and active treatment was noted. Among the procoagulatory factors, only factor VII activity was found to be increased over placebo in the active treatment group, but decreased in the placebo group. Protein C activity increased during the treatment with 30 micrograms ethinyl estradiol and 2.00 mg dienogest, and was higher than that of the placebo group in which this parameter decreased during the treatment cycle. There was a corresponding increase in fibrinolytic activity being reflected by higher plasminogen levels in the active treatment group in comparison with placebo. An increase was noted for the fibrinolytic parameter D-dimer. Apart from isolated measurements, the parameters remained in their respective normal ranges. The data combine to suggest that 30 micrograms ethinyl estradiol and 2.00 mg dienogest has a balanced effect on the hemostatic system stimulating both procoagulatory and fibrinolytic activity | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Biology | |
| 650 | 4 | |a Blood Coagulation Effects | |
| 650 | 4 | |a Case Control Studies | |
| 650 | 4 | |a Clinical Research | |
| 650 | 4 | |a Clinical Trials | |
| 650 | 4 | |a Contraception | |
| 650 | 4 | |a Contraceptive Methods--side effects | |
| 650 | 4 | |a Developed Countries | |
| 650 | 4 | |a Europe | |
| 650 | 4 | |a Family Planning | |
| 650 | 4 | |a Germany | |
| 650 | 4 | |a Hematological Effects | |
| 650 | 4 | |a Hemic System | |
| 650 | 4 | |a Oral Contraceptives, Combined--side effects | |
| 650 | 4 | |a Oral Contraceptives--side effects | |
| 650 | 4 | |a Physiology | |
| 650 | 4 | |a Research Methodology | |
| 650 | 4 | |a Research Report | |
| 650 | 4 | |a Studies | |
| 650 | 4 | |a Western Europe | |
| 650 | 7 | |a Contraceptives, Oral |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a Placebos |2 NLM | |
| 650 | 7 | |a Protein C |2 NLM | |
| 650 | 7 | |a prothrombin fragment 1.2 |2 NLM | |
| 650 | 7 | |a Ethinyl Estradiol |2 NLM | |
| 650 | 7 | |a 423D2T571U |2 NLM | |
| 650 | 7 | |a dienogest |2 NLM | |
| 650 | 7 | |a 46M3EV8HHE |2 NLM | |
| 650 | 7 | |a Nandrolone |2 NLM | |
| 650 | 7 | |a 6PG9VR430D |2 NLM | |
| 650 | 7 | |a Antithrombin III |2 NLM | |
| 650 | 7 | |a 9000-94-6 |2 NLM | |
| 650 | 7 | |a Factor VII |2 NLM | |
| 650 | 7 | |a 9001-25-6 |2 NLM | |
| 650 | 7 | |a Prothrombin |2 NLM | |
| 650 | 7 | |a 9001-26-7 |2 NLM | |
| 650 | 7 | |a Fibrin |2 NLM | |
| 650 | 7 | |a 9001-31-4 |2 NLM | |
| 650 | 7 | |a Fibrinogen |2 NLM | |
| 650 | 7 | |a 9001-32-5 |2 NLM | |
| 650 | 7 | |a Plasminogen |2 NLM | |
| 650 | 7 | |a 9001-91-6 |2 NLM | |
| 650 | 7 | |a Tissue Plasminogen Activator |2 NLM | |
| 650 | 7 | |a EC 3.4.21.68 |2 NLM | |
| 700 | 1 | |a Feichtinger, W |e verfasserin |4 aut | |
| 700 | 1 | |a Kindermann, C |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, B |e verfasserin |4 aut | |
| 700 | 1 | |a Mellinger, U |e verfasserin |4 aut | |
| 700 | 1 | |a Walter, F |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, C |e verfasserin |4 aut | |
| 700 | 1 | |a Gräser, T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Contraception |d 1972 |g 56(1997), 2 vom: 22. Aug., Seite 67-75 |w (DE-627)NLM000108367 |x 1879-0518 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:1997 |g number:2 |g day:22 |g month:08 |g pages:67-75 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 1997 |e 2 |b 22 |c 08 |h 67-75 | ||